Safety and Efficacy Study of Parkinson's Disease Gene Therapy Drug (BBM-P002)

Central South University

Status and phase: Completed; Early Phase 1

Conditions: Parkinson's Disease

Treatments: Drug: BBM-P002

Study type: Interventional

Funder types: Other

Identifiers

NCT05822739

BBM003- IIT1003

Details and patient eligibility

About

Safety and Efficacy Study of BBM-P002 in participants with primary advanced Parkinson's disease

Full description

Parkinson's disease is a neurodegenerative disorder involving loss of dopaminergic neurons in the substantia nigra. This study is a single-center, single-arm, open-label, treatment clinical study to evaluate the safety, tolerability and efficacy of an adeno-associated virus (AAV)-based gene therapy, termed BBM-P002, will be injected into the brain via a neurosurgical procedure.

Enrollment: 10 patients

Sex: All

Ages: 40 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Clinically confirmed diagnosis of idiopathic Parkinson's Disease (PD) in accordance with the 2015 Movement Disorder Society (MDS) diagnostic criteria.
2. Participants aged between 40 and 65 years, inclusive, of any gender.
3. A disease history of five years or more.
4. A Hoehn and Yahr (H-Y) stage of 2.5 to 4 in the Of-state.
5. An adeno-associated virus (AAV) neutralizing antibody titer of fit thecriteria.
6. A Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III score greater than 35 in the Off-state, with an improvement of at least 30% following an acute levodopa challenge test.
7. Stable anti-Parkinsonian medication regimen prior to the screening period for at least four weeks.
8. The subject must agree to postpone any other neurosurgical procedures (including deep brain stimulation) during the main study phase, with the exception of emergency neurosurgery for life-threatening conditions.
9. The subject must agree not to participate in other therapeutic interventional studies during the main study phase.
10. The subject must agree not to undergo vaccination during the main study phase.
11. Commitment to using a reliable method of contraception from the screening period until at least 52 weeks post-infusion.
12. The subject must be compliant and capable of attending regular follow-up appointments. The subject must be able to accurately complete a PD patient diary during the follow-up period, with assistance from family members, guardians, or caregivers permitted.
13. The subject must be fully informed about the nature, objectives, procedures, and potential adverse effects of the clinical trial, and must voluntarily consent to participate by signing the informed consent form. In cases where the subject is unable to read, a legally authorized representative or an impartial witness may read the informed consent form and other written materials to them and witness the consent process.

Exclusion criteria

1. Diagnosis of atypical or secondary parkinsonian syndromes (e.g., Parkinson-plus syndromes, hereditary parkinsonian syndromes, drug-induced parkinsonism).
2. Presence of surgical contraindications, a history of prior brain surgery such as deep brain stimulation (DBS), pallidotomy, or extrapyramidal surgery, or any other neurosurgical procedure that the investigator deems would interfere with participation in this trial.
3. Previous cranial imaging showing structural brain abnormalities, cerebrovascular malformations, intracranial tumors, risk of intracranial hemorrhage, traumatic brain injury, or other significant anomalies.
4. A Mini-Mental State Examination (MMSE) score of <24.
5. A Patient Health Questionnaire-9 (PHQ-9) score of ≥16.
6. Abnormal liver or kidney function, defined as: Aspartate aminotransferase (AST) or Alanine aminotransferase (ALT) >1.5 times the upper limit of normal (ULN), or serum creatinine (Cr) >1.5 times the ULN.
7. Coagulation dysfunction or current use of anticoagulant agents.
8. Positive screening for infectious diseases: positive for Hepatitis B surface antigen (HBsAg) or Hepatitis B virus DNA (HBV-DNA), positive for Hepatitis C virus RNA (HCV-RNA), positive for Human Immunodeficiency Virus (HIV), or seropositive for syphilis.
9. Currently undergoing antiviral treatment for Hepatitis B or C.
10. Presence of unstable or severe concomitant systemic diseases, including but not limited to active tuberculosis, or diseases of the cardiovascular, respiratory, digestive, urinary, neuropsychiatric (e.g., epilepsy), hematologic, or immune systems, or abnormal laboratory values that, in the judgment of the investigator, would make the subject unsuitable for the trial.
11. Current or prior history of a malignant tumor.
12. History of a severe allergic reaction, allergy to contrast agents, or inability to tolerate surgical anesthesia.
13. Current participation in another clinical trial, or participation in any other clinical trial within 3 months prior to the screening period.
14. Prior history of gene therapy before screening.
15. Receipt of stem cell therapy within 6 months prior to the screening period.
16. Use of other investigational drugs within 4 weeks prior to screening or within 5 half-lives of the drug (whichever is longer), or any medication judged by the investigator to interfere with the trial.
17. Receipt of a live vaccine within 2 months prior to the screening period, or any vaccination within 30 days prior to the screening period.
18. History of alcohol dependence or drug addiction, with an inability to adhere to medical advice to abstain from alcohol during the trial period.
19. Female subjectsparticipants who are pregnant or lactating.
20. Any subject deemed unsuitable for enrollment based on the investigator's assessment.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

10 participants in 1 patient group

Arm of BBM-P002

Experimental group

Description:

single-arm

Treatment:

Drug: BBM-P002